|
|
RythymAbstract: Clinical biosimilar data should be accessible to allFDA Form 483: punishment or learning opportunity?Biosimilars: challenges getting into the USBiosimilar regulatory issuesNew Amgen ‘182’ Enbrel patentInterchangeability or substitution of biosimilarsIs anyone developing biosimilars of darbepoetin alfa in Europe?Biosimilar patents expiring before 2020
|
